The Treatment of COVID-19 Purgatory Syndrome With Tocilizumab and Steroids.

Authors :: Selvaraj V
Finn A
Li J
Dapaah-Afriyie K
Source :: Cureus [Cureus] 2022 Feb 25; Vol. 14 (2), pp. e22614. Date of Electronic Publication: 2022 Feb 25 (Print Publication: 2022).
Publication Year :: 2022
Abstract: Hyperinflammation is a key component of severe coronavirus disease 2019 (COVID-19) and is associated with poor outcomes. It is imperative to distinguish severe COVID-19 from hyperinflammatory syndromes such as multisystem inflammatory syndrome (MIS) and hemophagocytic lymphohistiocytosis. There is a subset of post-COVID-19 patients who present with some symptoms characteristic of MIS in adults (MIS-A) yet do not meet all the criteria for a diagnosis. We describe the unique case of a patient with this kind of presentation who clinically improved following tocilizumab and corticosteroid usage.<br />Competing Interests: The authors have declared that no competing interests exist.<br /> (Copyright © 2022, Selvaraj et al.)